A new duet in cancer biology: AMPK the typical and UBE2O the atypical
Ubiquitin-conjugating enzyme E2O (UBE2O) is upregulated in human cancers. We have demonstrated that genetic deletion or pharmacological blockade of UBE2O reduces tumorigenesis through inhibiting the mammalian target of rapamycin complex 1–hypoxia-inducible factor 1-α pathway. Critically, UBE2O targe...
Main Authors: | Isabelle K. Vila, Su Jung Song, Min Sup Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-05-01
|
Series: | Molecular & Cellular Oncology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/23723556.2017.1304846 |
Similar Items
-
CTAB Enhances Chemo-Sensitivity Through Activation of AMPK Signaling Cascades in Breast Cancer
by: Yue Pan, et al.
Published: (2019-07-01) -
AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma
by: Eslam E. Abd El-Fattah, et al.
Published: (2022-01-01) -
TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation
by: Yongchang Chen, et al.
Published: (2022-01-01) -
The Positive Correlations between the Expression of Histopathological Ubiquitin-Conjugating Enzyme 2O Staining and Prostate Cancer Advancement
by: Jae-Heon Kim, et al.
Published: (2021-08-01) -
A novel AMPK activator shows therapeutic potential in hepatocellular carcinoma by suppressing HIF1α‐mediated aerobic glycolysis
by: Hsing‐I Tseng, et al.
Published: (2022-06-01)